LINTRIS

A global investor needed to assess the strategic and policy context behind China’s growing role as a source of biotech and digital health innovation — and translate that into clear implications for their investment thesis and external positioning. We delivered a structured intelligence brief and ongoing horizon scanning, distilling a complex and fast-moving policy environment into actionable analysis for a leadership team with limited prior exposure to the Chinese system.

A leading international think tank commissioning a white paper on the future of health innovation needed technical depth and insider perspective on China’s policy and regulatory environment that their in-house team could not provide. We contributed structured analysis on the policy, institutional and commercial forces shaping China’s biotech and digital health trajectory — translating complex system dynamics into clear, evidenced argument for a policy-literate but non-specialist audience.

A policy team at a major international biopharma needed credible, ongoing support to engage on China’s health policy and innovation environment — across trade association representation, internal upskilling and asset-specific reimbursement and access questions. We provided sustained senior advisory: translating fast-moving regulatory and policy developments into commercially actionable language, preparing the team for external forums, and mapping the stakeholder and regulatory context around specific products in market.

A dual-listed biopharma company required a coherent investor-facing narrative that positioned its China pipeline and market access strategy credibly for international audiences. We worked closely with the leadership team to develop the underlying strategic framing, draft investor communications, and align internal and external messaging across a complex, multi-market story.

A government ministry sought to convene a structured bilateral policy exchange with counterparts in East Asia on a shared chronic disease challenge, bringing together senior clinical, policy and diplomatic voices across both systems. We led end-to-end programme delivery — designing the agenda, securing participation from high-level stakeholders across government, academia and clinical practice, and managing facilitation and outputs. The exchange produced concrete shared recommendations and established an ongoing channel for bilateral technical dialogue.

A medtech company expanding into new international markets needed to build relationships with senior government, clinical and industry stakeholders in a system they did not know. We mapped the relevant networks, made targeted introductions, and supported the development of a partnership strategy grounded in an accurate understanding of how the system actually works — accelerating entry without the cost of learning from scratch.